After first-line induction therapy with FOLFOX-bevacizumab maintenance treatment with 5-FU plus atezolizumab has been also evaluated in the phase II MODUL trial which included patients with metastatic BRAF wild-type CRC. Here, BRAF is linked to colorectal carcinoma.